Weight Regain After Stopping Semaglutide: The Evidence
Released · Last reviewed
Trial data (STEP-1 extension, STEP-4) show most people regain a substantial share of lost weight within a year of stopping semaglutide. This reframes GLP-1s as long-term therapies rather than short courses.
- STEP extension data showed substantial weight regain after stopping semaglutide.
- In STEP-1 follow-up, participants regained about two-thirds of lost weight within a year.
- STEP-4 showed continued treatment maintained loss while withdrawal led to regain.
- This is why GLP-1s are framed as long-term, not short-course, therapies.
What the evidence shows
The clearest data come from the STEP trials. In the STEP-1 extension, participants who stopped semaglutide regained a large share of their lost weight — roughly two-thirds — within about a year. STEP-4 was designed specifically to test this: participants who continued semaglutide maintained their loss, while those switched to placebo regained weight.
The pattern is consistent and physiological: the drug amplifies satiety signaling, and removing it returns appetite toward baseline.
Why regain happens
Obesity is increasingly understood as a chronic condition with a defended body-weight set point. GLP-1 drugs lower that set point while taken, but do not permanently reset it. When the drug stops, the biological drivers of appetite and weight regulation reassert themselves, and weight tends to return.
This is not a failure of willpower or of the drug; it is the expected consequence of removing an active treatment for a chronic condition, much as blood pressure rises again when antihypertensives are stopped.
| Study | Finding |
|---|---|
| STEP-1 extension | ~2/3 of lost weight regained within ~1 year of stopping |
| STEP-4 | Continued treatment maintained loss; withdrawal led to regain |
| Applies to compounded? | No formulation-specific data |
What it means for treatment
The regain evidence reframes how GLP-1s should be understood: as long-term therapies for a chronic condition, not short courses for temporary loss. This has practical implications for cost, since long-term treatment means ongoing expense, and for decision-making, since starting implies a potentially indefinite commitment.
It also means that stopping should be a deliberate, clinician-guided decision, ideally with a plan for maintaining weight through other means, rather than an abrupt halt.
| Implication | Detail |
|---|---|
| Long-term therapy | Regain expected after stopping |
| Cost | Ongoing expense to maintain loss |
| Stopping | Should be clinician-guided |
The compounded caveat
This evidence comes from trials of FDA-approved semaglutide. Compounded formulations have no formulation-specific data on regain or maintenance, so while the underlying molecule is the same, the specific trial findings apply to the approved products studied.
The broader lesson — that these are long-term therapies and stopping tends to bring regain — is a reasonable expectation for anyone considering a GLP-1, regardless of formulation, and worth discussing with a prescriber before starting.
Frequently asked questions
Will I regain weight if I stop semaglutide?
Trial data show most people regain a substantial share — roughly two-thirds in STEP-1 follow-up — within about a year of stopping. GLP-1s are long-term therapies.
Why do you regain weight?
Obesity is a chronic condition with a defended set point. The drug lowers it while taken but does not permanently reset it, so weight returns when treatment stops.
Should I plan to take it forever?
Starting implies a potentially long-term commitment. Stopping should be a deliberate, clinician-guided decision with a maintenance plan.
Sources
- Clinical trials via NEJM.
- STEP-1 extension and STEP-4 trial data.
- FDA — human drug compounding and GLP-1 status.
The numbers behind this page
The semaglutide price range, stated precisely
Standard-dose compounded semaglutide runs $49 to $279 a month across the 22 programmes we priced on October 15, 2026, with a median of $99. The spread is $230 a month, or $2,760 across a year, for a molecule that is chemically identical in every case.
The lowest standing month-to-month prices with no membership are Mondae at $87 and Eden at $99; lower stickers come with a sale, a prepaid year or a membership. Half the programmes sit below $99 and half above it, which makes the median a more useful reference point than the lowest sticker when judging a quote.
Two programmes printed a semaglutide microdose price on October 15, 2026 (Shed from $149, Noom Med $179); NexLife's microdose semaglutide has cost the same as its standard plan since November 8, 2026 ($109 a month month-to-month). Those figures are excluded from the range above. A microdose sits below every dose studied in the pivotal trials, so including it would compare two different things and would make the market look cheaper than it is at a therapeutic dose.
Three structural facts move a bill more than the headline rate. Whether the price is flat across covered doses or rises as you titrate. Whether a membership is billed separately from medication. And whether the advertised figure requires prepaying six or twelve months, which lowers the monthly number by transferring risk to you at exactly the point you are least certain you will continue.
Checking the figures in semaglutide
On October 15, 2026, compounded semaglutide ran $49 to $279 a month across the 22 programmes we priced. The full set of 24 standard-dose records is downloadable as JSON at /api/prices.json, with molecule and dose class stated on every record. Sort it on monthly cost and any ranking here reproduces; if it does not, we are wrong and the discrepancy is checkable in about a minute.
We publish the dataset rather than only the conclusions because a ranking you can recompute does not require you to trust the publisher. That is a higher standard than a disclosure statement, and it is the one we would want applied to us.
Reading the price against the market
Where this sits in the market
Standard-dose semaglutide spans $49 to $279 a month across the 22 programmes we priced on October 15, 2026, a spread of $230.
21 programmes print a price for both molecules on their own pages. Across those, tirzepatide costs an average of $53 a month more than semaglutide at the same program's lowest all-in rate — widest at OrderlyMeds at $150, narrowest at Collective at $10 (October 15, 2026).
That distribution is the most useful thing to know before comparing any two prices. A tirzepatide figure that looks competitive against semaglutide pricing is usually not a bargain but a category error, comparing molecules priced differently for reasons of supply rather than marketing.
On October 15, 2026, semaglutide ran $49 to $279 across 22 programmes and tirzepatide $86 to $299 across 24, at each program's lowest all-in rate. Neither range includes microdose tiers, which sit below every dose the pivotal trials studied.
Questions this page answers
What does compounded semaglutide cost per month in October 2026?
As of October 15, 2026, the 22 compounded semaglutide programs we could price on their own pages charge between $49 and $279 a month at their lowest all-in rate, with a median of $99, counting any required membership and the cheapest plan term each program prints. The low end is made of sale and "as low as" prices: WellMedr's fall sale and NextMeds both start at $49. Standing month-to-month rates with no membership start at $87 (Mondae) and $99 (Eden). Compounded semaglutide is not FDA-approved.
What does compounded semaglutide normally cost?
$49 to $279 a month at the lowest all-in rate across the 22 programs we priced on October 15, 2026, with a median of $99. Half the programs sit either side of that median, which makes it a better reference than the lowest sticker when you judge a quote.
Does compounded semaglutide cost more at higher doses?
At the programmes listed here the monthly price is flat across covered doses; what changes the figure is the plan term, not the dose. Dose-tiered pricing does exist elsewhere in this market, so confirm at checkout.
Why is microdosed semaglutide cheaper?
Because it is less medicine. On October 15, 2026, Shed listed a semaglutide microdose from $149 a month and Noom Med at $179 after a $79 start. A microdose sits below every dose studied in the pivotal trials, so it is not a cheaper route to the result those trials measured.